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A B S T R A C T
Multiresistance in Gram-negative pathogens, particularly Pseudomonas aeruginosa, Stenotrophomonas
maltophilia, Acinetobacter spp. and the Enterobacteriaceae, is a significant problem in medicine today.
While multiple mechanisms often contribute to multiresistance, a broadly distributed family of three-
component multidrug efflux systems is an increasingly recognised determinant of both intrinsic and
acquired multiresistance in these organisms. Homologues of these efflux systems are also readily
identifiable in the genome sequences of a wide range of Gram-negative organisms, pathogens and non-
pathogens alike, where they probably promote efflux-mediated resistance to multiple antimicrobials.
Significantly, these systems often accommodate biocides, raising the spectre of biocide-mediated
selection of multiresistance in Gram-negative pathogens. While there is some debate as to the natural
function of these efflux systems, only some of which are inducible by their antimicrobial substrates, their
contribution to resistance in a variety of pathogens nonetheless makes them reasonable targets for
therapeutic intervention. Indeed, given the incredible chemical diversity of substrates accommodated by
these efflux systems, it is likely that many novel or yet to be discovered antimicrobials will themselves be
efflux substrates and, as such, efflux inhibitors may become an important component of Gram-negative
antimicrobial therapy.
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I N T R O D U C T I O N
While it is clear that bacterial resistance to
antimicrobials pre-dates their clinical use, medical
and agricultural practices of the past 50 years or
more have promoted resistance development and
spread in both human and animal pathogens,
thereby compromising effective chemotherapy
of infectious diseases. While much attention is
focused currently on Gram-positive and myco-
bacterial pathogens, Gram-negative bacteria,
particularly those exhibiting a multiresistance
phenotype, can still pose a serious infectious
disease threat [1,2]. Resistance to multiple antibi-
otics is increasingly seen in the Enterobacteria-
ceae, Pseudomonas aeruginosa, Stenotrophomonas
maltophilia and Acinetobacter spp. [3]. Significantly,
infections caused by such multiresistant
Gram-negative pathogens are associated with
excess morbidity and mortality [4–8].
Resistance to antibiotics occurs typically as a
result of drug inactivation or modification, target
alteration, or reduced accumulation associated
with decreased permeability and ⁄ or increased
efflux [9]. It may be an intrinsic feature of an
organism, or may result from mutation or the
acquisition of exogenous resistance genes [10,11].
Thus, multiresistance typically results from the
accumulation of multiple mutations and ⁄ or resist-
ance genes (e.g., on integrons [12]), but specific
growth states (e.g., biofilms) and single mutations
(e.g., impacting on outer-membrane permeability
or the expression of broadly specific multidrug
efflux systems) can also promote multiresistance
[13]. This review highlights recent advances in
our understanding of efflux-mediated multire-
sistance in Gram-negative bacteria, including
updates on the distribution of efflux systems in
these organisms, their substrate profiles, and their
contribution to antimicrobial resistance in clinical
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strains. The ongoing discussions concerning the
natural function of these efflux systems and their
possible involvement in biocide-mediated selec-
tion of antibiotic-resistant strains will also be
highlighted. The interested reader is referred to
other recent reviews for a more comprehensive
treatment of the subject [13,14].
M U L T I D R U G E F F L U X
While efflux as a mechanism of resistance to
individual agents has been known for some time,
multidrug efflux systems have only recently been
identified and appreciated as significant determi-
nants of resistance [14,15]. Chromosomally enco-
ded and broadly distributed in Gram-negative
bacteria [16], these systems play an important role
in intrinsic and acquired multiresistance [13,14].
Bacterial efflux systems capable of accommoda-
ting multiple antimicrobials fall into five classes:
the major facilitator superfamily (MFS); the ATP-
binding cassette (ABC) family; the resistance-
nodulation-division (RND) family; the small
multidrug resistance (SMR) family (a member of
the much larger drug ⁄metabolite transporter
(DMT) superfamily); and the multidrug and
toxic compound extrusion (MATE) family [17].
Although not unique to Gram-negative bacteria,
RND family transporters are most commonly
found in such organisms and typically operate as
part of a tripartite system that includes a periplas-
mic membrane fusion protein (MFP) and an outer-
membrane protein (now called outer-membrane
factor (OMF)) [18], an organisation also seen on
occasion with MFS (e.g., EmrAB-TolC; see below)
and ABC (e.g., the macolide-specific MacAB-TolC
efflux system [19]) transporters (Fig. 1). Members
of all but the ABC family (whose members
hydrolyse ATP to drive drug efflux) function as
secondary transporters, catalysing drug–ion
(H+ or Na+) antiport (Fig. 1).
R N D F A M I L Y O F M U L T I D R U G
E F F L U X S Y S T E M S
The most relevant multidrug efflux systems in
terms of resistance to clinically important agents
(including antibiotics and biocides) are members of
the RND family [13] (Table 1), although members
of the MFS, MATE and SMR families also show a
limited ability to promote resistance to some
biocides and antibiotics (Table 2). Originally iden-
tified as determinants of fluoroquinolone resist-
ance in a number of Gram-negative pathogens [20],
efflux systems of the RND–MFP–OMF type are
known to accommodate a broad range of structur-
ally unrelated molecules that can include most
classes of antibiotics, as well as biocides, dyes,
detergents, metabolic inhibitors, aromatic hydro-
carbons (i.e., organic solvents), cationic antimicro-
bial peptides, toxic fatty acids, bile salts, and
homoserine lactones associated with quorum-sens-
ing [13,21]. These last play a role in cell density-
dependent expression of a number of virulence
factors in (for example) P. aeruginosa, and thus the
activity of these efflux systems can influence
virulence [22,23]. Indeed, a recent study suggests
that the MexAB–OprM efflux system of P. aerugi-
nosa may promote the release of molecule(s)
important for the virulence of this organism [24].
RND–MFP–OMF multidrug efflux systems
contributing to antimicrobial resistance have been
described in a broad range of Gram-negative
pathogens (human, animal, plant) and non-path-
ogens (Table 1). In view of the role played by
RND–MFP–OMF-type multidrug efflux systems
in efflux-mediated fluoroquinolone resistance,
reports of efflux-mediated resistance to fluoro-
quinolones in Vibrio cholerae [25], Citrobacter
freundii [26] and Proteus vulgaris [27] may also
be indicative of multidrug efflux systems in
these organisms. The best characterised efflux
systems of the RND–MFP–OMF group are those
found in Escherichia coli [28], P. aeruginosa [21] and
Neisseria gonorrhoeae [29], and homologues of
these systems are readily identifiable in both
finished genome sequences (see Table 1 for
Fig. 1. The organisation and operation of antimicrobial
efflux pumps of Gram-negative bacteria. OM, outer mem-
brane; PP, periplasmic space; CM, cytoplasmic membrane.
Poole Efflux-mediated multiresistance 13
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 12–26
Table 1. RND family multidrug efflux systems of Gram-negative bacteria
Organism
Efflux componentsa
Regulatory
genes Expressionb Substratesc Reference(s)MFP RND OMF
Acinetobacter
baumannii
AdeA AdeB AdeC adeSTd wt ⁄+ AG, CX, TC,
ER, CM, TP,
FQ
[45]
Agrobacterium
tumefaciens
AmeA AmeB AmeC ameR wt ⁄+ BS, NV, SDS [102]
Brucella suis AcrAe AcrBe ? gntRf ? ?
(AAN34087) (AAN34086) (AAN34085)
Brucella
melitensis
AcrAe
(AAL52073)
AcrBe
(AAL52074)
acrRf
(AAL52072)
? ?
Burkholderia
cepacia
CeoA
(U97042)g
CeoB
(U97042)g
OpcM ? wt ⁄ –;
mutant ⁄+
CM, CP, TP –h
Burkholderia
pseudomallei
AmrA AmrB OprA amrR wt ⁄+ ML, AG –h
Campylobacter
jejuni
CmeA CmeB CmeC ? wt ⁄+;
mutant ⁄ ?
FQ, ER, BL,
RF, TC, EB,
SDS, DOC, CM,
GN, ACR
[103,104]
Caulobacter
crescentus
AcrAe
(AAK22793)
AcrBe
(AAK22792)
? ? ? ?
Enterobacter
aerogenes
AcrA AcrB TolC acrR wt ⁄ ?;
mutant ⁄++
FQ, CM, TC,
ACR, NOV, SDS,
BS
[32]
Enterobacter
cloacae
? AcrB ? ? CIP [33]
Escherichia
coli K12
AcrA AcrB TolC acrR, marA,
robA, soxS,
sdiAl
wt ⁄+;
marR ⁄++j;
acrR ⁄++
AHk, BA, BL,
NV, ER, FU,
FQ, TC, CM,
EB, AC, CV,
SDS, TX, BS,
TS, PO, FA,
MXk, LNk
–h
AcrE AcrF TolC acrS, sdiAl wt ⁄ –;
mutant ⁄+
AH, FQ, TC,
TP, LN, ML,
BS, SDS, AC,
RD, BLm
–h
AcrA AcrD TolC sdiAl, baeRkk,
cpxRk, ompRkk
wt ⁄+ AG, NV, DOC,
SDSn BLll
–h
MdtA
(YegM)
MdtB ⁄MdtC
(YeN ⁄YegO)
TolC baeSR wt ⁄ –o NV, BLll, BS, SDS [54,105,106]
YhiU YhiV TolC evgA wt ⁄ –o ER, NV, DOX,
CV, EB, SDS,
BS, BA, RDo, BLll
[54,107–109]
Escherichia
coli O157:H7
AcrAp
(BAB33939)
AcrBp
(BAB33938)
TolCp
(BAB37346)
acrRp
(BAB33940)
? ?
? AcrDp
(BAB36755)
? ? ? ?
Haemophilus
influenzae
AcrA AcrB ? ? wt ⁄+ RF, ER, NV,
EB, AC, CV,
SDSq
–h
Klebsiella
oxytoca
AcrA AcrB ? ? wt ⁄ ?;
mutant ⁄+
FQ [34]
Klebsiella
pneumoniae
AcrAp
(AJ318073)
AcrBp
(AJ318073)
? acrRp
(AJ318073)
wt ⁄ ?;
mutant ⁄+
FQ [34]
Neisseria
gonorrhoeae
MtrC MtrD MtrE mtrR, mtrA wt ⁄+;
mtrR ⁄++
mtrA ⁄ –
AZ, ML, RF,
PN, TXr, CV,
CP
–h
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Table 1. continued
Organism
Efflux componentsa
Regulatory
genes Expressionb Substratesc Reference(s)MFP RND OMF
Neisseria
meningitidis
MtrC
(CAB85190)
MtrD
(CAB85189)
MtrE
(CAB85188)
mtrR
(CAB85191),
mtrA
(CAB85011)
? ?
Porphyromonas
gingivalis
XepA XepB XepC ? wt ⁄+ RF, PM, EB [110]
Proteus
mirabilis
AcrA AcrB ? acrR wt ⁄+ TG, MN, CP,
NV, CM, ER,
EB, AC, TP,
SDS
[80]
Pseudomonas
aeruginosa
MexA MexB OprM mexR wt ⁄+;
nalB ⁄+++;
nalCs ⁄++;
BLt, FQ, CM,
NV, TP, TGt
SM, EB, AC,
CV, SDS, AH,
HL, CL, TL,
IR, TS, TPP,
RD
–h
MexC MexD OprJ nfxB wt ⁄ –u;
nfxB ⁄++
BLv, FQ, CM,
NV, TP, TGt,
SM, EB, AC,
SDS, AH, CL,
TS, TGv, TPP,
RD
–h
MexE MexF OprN mexT wt ⁄ –;
nfxCw ⁄++
FQ, CM, TP,
AH, TS
–h
MexX
(AmrA)
MexY
(AmrB)
OprM mexZ
(amrR)
wt ⁄+ BLx, FQ, AG,
TC, ER, TGx
–h
MexJ MexK OprM mexL wt ⁄ –;
mutant ⁄+
TSy, ER, TC,
CP
[57]
MexH MexI OpmD ? wt ⁄ ?;
mutant ⁄+
VA, HL?, EB,
NOR, RD, AC
[111,111a]
MexV MexW OprM ? wt ⁄ ?;
mutant ⁄+
FQ, CM, TC,
ER, EB, AC
[111b]
pa1435z
(AAG04824)
pa1436z
(AAG04825)
? ? ? ?
pa3523z
(AAG06911)
pa3522z
(AAG06910)
pa3521z
(AAG06909)
? ? ?
pa0156 ⁄
pa0157z
(AAG03546 ⁄
AAG03547)
pa0158z
(AAG03548)
? ? ? ?
pa2528z
(AAG05916)
pa2526 ⁄
pa2527z
(AAG05914 ⁄
AAG05915)
pa2525z
(AAG05913)
? ? ?
Pseudomonas
putida
ArpA ArpB ArpC arpR wt ⁄+ TC, CM, CB,
ST, ER, NV
–h
MepA MepB MepC mepR ? BL, TC, NV,
ER, AH
–h
SrpA SrpB SrpC srpR, srpS wt ⁄+aa AH –h
TtgA TtgB TtgC ttgRii wt ⁄+ CM, AP, TC,
TO
–h
TtgD TtgE TtgF ? wt ⁄+aa AH –h
TtgG TtgH TtgI ttgVjj wt ⁄+;
inducible
++bb
AH, AP, CB –h
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Table 1. continued
Organism
Efflux componentsa
Regulatory
genes Expressionb Substratesc Reference(s)MFP RND OMF
Salmonella
enterica
serovar
Typhimurium
AcrAp
(AAL19430)
?
AcrBp
(AAL19429)
AcrDp
(AAL21375)
TolCp
(AAL22060)
?
acrRp
(AAL19431)
soxRScc
wt ⁄+;
mutant ⁄++
soxR ⁄++
BS, SDS, DOC,
CH, TX, CV,
AC, FA, NV,
ER, RF, TC,
CM, NOR, NAL,
BL, FQdd
–h
Salmonella
enterica
serovar
Typhi
AcrAp
(CAD04961)
?
AcrBp
(CAD04960)
AcrDp
(CAD07711)
TolCp
(CAD07712)
?
acrRp
(CAD04962)
?
?
?
Serratia
marcescens
AcrA AcrB ? ? ? FQ [47,112]
SdeX SdeY ? ? ? ER, TC, NOR,
BA, EB, AC, RD
[112a]
Shewanella
oneidensis
AcrAe
(AAN57652)
AcrBe
(AAN57651)
TolC ? ? AQDSee
Shigella
flexneri
AcrAp
(AAN42063)
AcrBp
(AAN42062)
TolCp
(AAN44553)
acrRp
(AAN42064)
?
Stenotrophomonas
maltophilia
SmeA SmeB SmeC smeRS ? BL, AG, FQ –h
Vibrio
cholerae
SmeD
?
SmeE
?
SmeF
TolChh
smeTff
?
wt ⁄+gg;
mutant ⁄++
wt ⁄+
TC, ER, FQ,
EB, ER, NV,
TX
–h
–h
AcrAe
(AAF96540)
AcrBe
(AAF96539)
? ? ? ?
Xanthamonsa
campestris
AcrAe
(AAM41645)
AcrBe
(AAM41646)
acrR ⁄ tetRf
(AAM41644)
? ?
MexAe
(AAM41955)
MexBe
(AAM41954)
OprMe
(AAM41953)
acrR ⁄ tetRf
(AAM41956)
? ?
Xylella
fastidiosa
AcrAe
(AAF85183)
AcrBe
(AAF85184)
? ? ? ?
AcrAe
(AAF83052)
AcrBe
(AAF83056)
? ? ? ?
Yersinia
pestis
AcrAp
(CAC92367;
AAM84631)
AcrBp
(CAC92368;
AAM84630)
TolCp
(CAC89517)
acrRp
(CAC92366;
AAM84632)
? ?
AcrAe AcrBe ? ? ? ?
(AAM84290) (AAM84291)
AcrDp
(CAC92285)
? ? ? ?
aWhere the efflux genes ⁄ gene products have not been published or their role in antimicrobial efflux and resistance has not
been verified, the GenBank protein (three-letter prefix) or gene (one-letter prefix) accession number is shown in parentheses.
bwt ⁄+, efflux system is known to be expressed in wild-type cells (under laboratory growth conditions); wt ⁄+ mutant ⁄++,
efflux system is expressed in wild-type cells but expression is enhanced in resistant strains; wt ⁄ – mutant ⁄+, efflux system is not
expressed in wild-type cells but is expressed in resistant strains. In instances where the nature of the mutation leading to
enhanced efflux gene expression is known, the gene is indicated along with the relative level of gene expression.
cAC, acriflavine; ACR, acridines; AG, aminoglycosides; AH, aromatic hydrocarbons; AP, ampicillin; AQDS, anthaquinone-
2,6-disulphonate; AZ, azithromycin; BA, benzalkonium; BL, b-lactams; BS, bile salts; CB, carbenicillin; CH, cholate; CL,
cerulenin; CM, chloramphenicol; CP, ciprofloxacin; CV, crystal violet; CX, cefotaxime; DOC, deoxycholate; DOX,
doxyrubicin; EB, ethidium bromide; ER, erythromycin; FA, fatty acids; FU, fusaric acid; FQ, fluoroquinolones; GN,
gentamicin; HL, homoserine lactones; IR, irgasan; LN, linezolid; ML, macrolides; MN, minocycline; MX, methotrexate;
NAL, nalidixic acid; NOR, norfloxacin; NV, novobiocin; PM, puromycin; PN, penicillin; PO, pine oil; RD, rhodamine; RF,
rifampicin; SDS, sodium dodecyl sulphate; SM, sulphonamides; ST, streptomycin; TC, tetracycline; TG, tigecycline; TL,
thiolactomycin; TO, toluene; TS, triclosan; TP, trimethoprim; TPP, tetraphenyl phosphonium; TX, Triton X-100; VA,
vanadium. In instances where only one member of a class of antimicrobial has been tested or is known to be a substrate for
a given pump, that member is identified. Where several members of an antimicrobial class are known to be substrates, the
class is identified rather than the actual compounds tested.
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Table 1. footnotes continued
dThe adeST genes, encoding homologues of the sensor kinase/response regulator members of the superfamily of bacterial
two-component regulators, were identified upstream of the ameABC efflux genes and implicated in regulating efflux gene
expression. No experimental evidence supporting this was provided.
eHomologues of the E. coli AcrAB efflux components were identified by a tBlastn search of the genome sequences of the
indicated organisms and the corresponding GenBank protein accession number shown in parentheses.
fExamination of gene sequences flanking the corresponding acrAB-like efflux genes in the genome sequences of the
indicated organisms identified homologues of regulatory genes of the indicated family upstream of the efflux genes,
implicating them in the regulation of these efflux genes.
gThe ceoAB genes (accession number provided in parentheses) and their contribution to efflux-mediated multiresistance
genes have not yet been published.
hExcept where indicated, accession numbers and references in support of efflux ⁄ regulatory gene identification and
substrate profiles are provided in recent review articles [13,14,20,21].
isdiA encodes a quorum-sensing regulator that positively regulates efflux gene expression [113,114].
jMarR negatively regulates marA gene expression, such that mutations in marR (in so-called mar mutants) lead to increased
MarA production and, thus, increased acrAB expression.
kContribution of AcrAB–TolC to resistance to aromatic hydrocarbons [115], methotrexate [116] and linezolid [117,117a] has
recently been confirmed.
lsdiA encodes a quorum-sensing regulator that positively influences efflux gene expression.
mContribution of AcrEF–TolC to resistance to antibiotics [117], dyes and detergents [54] and aromatic hydrocarbons [118]
has recently been demonstrated.
nContribution of AcrD to resistance to non-aminoglycosides has recently been reported [54].
The efflux genes are not expressed and do not contribute to antimicrobial resistance in wild-type cells, although their
cloning on a multicopy plasmid promotes resistance to (and probably efflux of) the indicated agents.
pOrthologues of the acrAB efflux genes were identified by a tBlastn search of the genome sequences of the indicated
organisms and the corresponding GenBank protein accession number shown in parentheses.
qData concerning substrate profile were ascertained by examining the susceptibility of an acrAB deletion mutant. It is not
clear, however, if the apparent differences in substrate profiles between AcrAB in H. influenzae and its homologues in E. coli
and S. enterica are real, or whether this pump actually accommodates many more substrates but its highly permeable outer
membrane compromises measurable net efflux in this organism.
rFull MtrCDE-mediated resistance to Triton X-100 requires the product of the recently identified mtrF gene, encoding a
probable cytoplasmic membrane protein of 56 kDa containing 12 transmembrane domains [119].
sThe nalC gene (also known as pa372) as designated by the Pseudomonas Genome Project (http://www.pseudomonas.com) is un-
linked to the mexAB–oprM genes, but encodes a TetR family repressor whose inactivation leads to mexAB–oprM hyperexpression.
tMexAB–OprM accommodates many penicillins and cephems [120], provides modest resistance to a few carbapenems (not
imipenem) [121] and is the major efflux system contributing to penem resistance in P. aeruginosa [122]. Recently, MexAB–
OprM-mediated resistance to the glycylcycline tigecycline has been reported [78].
uAlthough MexCD–OprJ is not expressed in wild-type cells under normal growth conditions, it is inducible by several of its
known substrates, including ethidium bromide, acriflavine, rhodamine 6G, tetraphenylphosphonium chloride, benzalk-
onium chloride and chlorhexidine [84,84a].
vMexCD–OprJ accommodates many penicillins and cephems [120], provides modest resistance to a limited number of
carbapenems (not imipenem) [121], and promotes modest resistance to penems in the absence of MexAB–OprM [122]. A
contribution to tigecycline resistance has also now been reported [78].
wThe nfxC gene has not yet been identified.
xMexXY–OprM accommodates several penicillins and cephems [120] and provides modest resistance to a limited number
of carbapenems (not imipenem) [121].
yEfflux of triclosan, but not the other antimicrobials, is provided by MexJK alone without OprM involvement.
zHomologues of the known P. aeruginosa multidrug efflux systems were identified by a blast search of the P. aeruginosa
genome sequence and are identified by the ‘pa’ designations provided by the Pseudomonas Genome Project (http://
www.pseudomonas.com) and the GenBank protein accession numbers (in parentheses).
aaExpression is inducible by aromatic hydrocarbons.
bbExpressed in wild-type cells with enhanced expression occurring in the presence of aromatic hydrocarbons.
ccSee Koutsolioutsou et al. [123].
ddContribution of AcrAB–TolC to fluoroquinolone resistance has recently been reported [124].
eeTolC-dependent export of AQDS (anthaquinone-2,6-disulphonate) has been demonstrated [125], although it is not clear
whether by a mechanism that involves the AcrAB homologues identified in Shewanella oneidensis.
ffsmeT encodes a repressor of smeDEF expression [126].
ggSmeDEF contributes to intrinsic multiresistance in S. maltophilia [127].
hhWhile TolC has been implicated in resistance to the indicated agents in V. cholerae, it is unclear if the AcrAB homologues
identified in this organism work with TolC in providing this resistance.
iiMediates drug inducibility of TTgABC [127a].
jjEncodes a repressor of ttgGHI expression [127b].
kkSee [127c]. llsee [127d].
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Table 2. Non-RND family multidrug efflux systems of Gram-negative bacteria
Source
Efflux components
Regulatory
gene(s) Expressiona Substratesb Reference(s)ABC MATE MFS SMR
Chromosomal
Bacteroides
fragilis
– – NorA? – ? wt ⁄+;
mutant ⁄++
NOR, EB, PM –c
Bacteroides
thetaiotaomicron
BexA – – – ? wt ⁄+;
mutant?
FQ, EB [128]
Bordetella
pertussis
– – – BPsmr ? ? MV, TPP, EB,
ACR
[129]
Brucella
melitensis
– NorMI – – ? ? FQ, GN, TPP,
ACR, BER
[130]
Burkholderia – – BcrA – ? ? TC, NAL [131]
cepacia
Burkholderia – NorM – – ? ? NOR [132]
vietnamiensis
Escherichia
coli
– – EmrBd – emrR
(mprA)
wt ⁄ –;
mutant ⁄ ?e
NAL, PMA, HU, TL –c
– – EmrD – ? wt ⁄ –;
mutant ⁄ ?e
HU –c
– – – EmrE (MvrC) ? wt ⁄+ EB, ACR, MPP,
MV, TC, TPP
–c
– – MdfA
(CmlA
and
Cmr)
– ? wt ⁄+ AG, BA, CM, –c
DM, EB, ER,
FQ, IPTG, PM,
RD, RF, TC,
TPP
– – – TehAf ? wt ⁄ –;
mutant ⁄ ?e
CV, EB, PF,
TPC
–c
– YdhE
(NorM)
– – ? ? NOR, CP, AC,
TPP, AG
–c
Neisseria
gonorrhoeae
NorM ? ? EB, AC, NOR,
CP, BA
[133]
Neisseria
meningitidis
– NorM – – ? ? EB, AC, NOR,
CP, BA
[133]
Pseudomonas
aeruginosa
– – – EmrE ? wt ⁄+ EB, ACR, MV,
AG
[129,134]
Vibrio
cholerae
– – VceBg – ? wt ⁄+ DOC, CCCP, CM,
ER, PMA, PCP,
NAL
–c
Vibrio
parahaemolyticus
– NorMh – – ? ? NOR, CP, AG,
EB
–c
VmrA ? ? TPP, ACR, EB [135]
Plasmid-encoded
– – – QacE ? NAj EB, PF, CV,
QAC
–c
– – – QacED1 ? NAj EB, PF, CV,
QAC
–c
McbFi – – – emrR
(mprA)
NAj FQ, HU –c
aRelative expression of the corresponding efflux system is indicted in wild-type (wt) cells (where known) and in mutants
known to express the system. In instances where the nature of the mutation leading to enhanced efflux gene expression is
known, the gene is indicated along with the relative level of gene expression. wt ⁄+ mutant ⁄++, efflux system is expressed
in wild-type cells (under laboratory growth conditions) but expression is enhanced in resistant strains; wt ⁄ – mutant ⁄+,
efflux system is not expressed in wild-type cells but is expressed in resistant strains; ?, expression status unknown.
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examples) and unfinished genome sequences
(e.g., Bordetella pertussis, Bordetella parapertussis,
Bordetella bronchiseptica, Burkholderia mallei, Legio-
nella pneumophila, Pasteurella multocida and Pseu-
domonas syringae; http://www.ncbi.nlm.nih.gov/
cgi-bin/Entrez/genom_table_cgi) of a number of
Gram-negative bacteria, although their contribu-
tion to antimicrobial resistance in these organisms
remains to be determined. Increasingly, multi-
drug efflux systems of the RND–MFP–OMF type
are implicated in clinical episodes involving
antibiotic-resistant organisms. Examples include
E. coli [30,31], Enterobacter aerogenes [32,32a],
Enterobacter cloacae [33], Klebsiella spp. [34].,
N. gonorrhoeae [35–37], Salmonella enterica ser-
ovar Typhimurium [38–41,41a], P. aeruginosa
[42,43,43a,b], S. maltophilia [44], Acinetobacter bau-
mannii [45], Burkholderia cepacia [46] and, possibly,
Serratia marcescens [47] and Campylobacter jejuni
[48]. Additional references can be found in other
recent review articles [13,20,21]. Efflux-mediated
fluoroquinolone resistance in clinical isolates of
C. freundii [26], Ent. aerogenes [49], Ent. cloacae [33]
and Klebsiella pneumoniae [50,51] may also be
attributable to multidrug efflux systems.
A N T I B I O T I C – B I O C I D E C R O S S -
R E S I S T A N C E
The observation that RND–MFP–OMF efflux
systems in both E. coli (AcrAB [52–54]) and
P. aeruginosa (MexAB–OprM [55], MexCD–OprJ
[56], MexEF–OprN [56] and MexJK [57]) accom-
modate both biocides and clinically important
antibiotics has added fuel to the debate on
biocide–antibiotic co-resistance and the possible
selection of multiply antibiotic-resistant strains by
biocides [9,58–64,64a]. While it appears that such
multidrug efflux systems are unlikely to facilitate
resistance to biocides used at the recommended
‘working’ concentrations of these agents, the risk
of residual biocide levels selecting pump-produ-
cing mutants that are concomitantly resistant to
clinically relevant antibiotics is of some concern
[65]. Certainly, in-vitro studies have confirmed
that biocide-resistant strains which overexpress
multidrug efflux systems, and thus become resist-
ant to multiple antibiotics, can be selected in both
E. coli [52,53] and P. aeruginosa [56]. Given the
broad distribution of Mex- and Acr-like efflux
systems in Gram-negative bacteria (see above and
Table 1), the risk of efflux-mediated biocide–anti-
biotic cross-resistance in other pathogens is a real
possibility.
E F F L U X S Y N E R G Y W I T H O T H E R
R E S I S T A N C E M E C H A N I S M S
The intrinsic and acquired resistance of Gram-
negative bacteria invariably depends upon
reduced antimicrobial accumulation, with or
without antimicrobial modification or destruction
or target site alterations [13]. The former comes
about as a result of the synergy between the
Table 2. footnotes continued
bAC, acriflavine; ACR, acridines; AG, aminoglycosides; BA, benzalkonium; BER, berberine; CCCP, carbonyl3 cyanide
m-chlorophenylhydrazone; CM, chloramphenicol; CP, ciprofloxacin; CV, crystal violet; DM, daunomycin; DOC,
deoxycholate; EB, ethidium bromide; ER, erythromycin; FQ, fluoroquinolones; GN, gentamicin; HU, hydrophobic
uncouplers; IPTG, isopropyl-b-D-thiogalactopyranoside; MPP, methyltriphenylphosphonium; MV, methyl vialogen; NAL,
nalidixic acid; NOR, norfloxacin; PCP, pentachlorophenol; PF, proflavin; PM, puromycin; PMA, phenylmercuric acetate;
QAC, quaternary ammonium compounds; RD, rhodamine; RF, rifampicin; TC, tetracycline; TL, thiolactomycin; TPC,
tetraphenylarsonium chloride; TPP, tetraphenyl phosphonium. In instances where only one member of a class of
antimicrobial has been tested or is known to be a substrate for a given pump, that member is identified. Where several
members of an antimicrobial class are known to be substrates, the class is identified rather than the actual compounds
tested.
cAccession numbers and references in support of efflux ⁄ regulatory gene identification and substrate profiles are provided
in recent review articles [13,14,20].
dPart of a probable three-component export system that includes the MFP component, EmrA, and the OMF component, TolC.
eEfflux activity and ⁄ or drug resistance has only been shown for the gene cloned on a plasmid.
fPart of a two-component export system that includes TehB.
gPart of a two-component export system that includes the MFP component VceA.
hFirst described in V. parahaemolyticus, NorM homologues (ascertained using BLAST searches) are found in the genome
sequences of a broad range of Gram-negative organisms, including most of those listed in Table 1.
iPart of a two-component export system that includes McbE.
jNot applicable.
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outer-membrane barrier and active efflux mech-
anisms, and disruption of either is effective in
enhancing accumulation and, thus, susceptibility
[66]. The importance of this synergy is highligh-
ted by the concomitant decline in porin pro-
duction, which decreases outer-membrane
permeability to, for example, hydrophilic agents,
and the increase in efflux activity that is seen in
so-called multiple antibiotic-resistant or mar
mutants of E. coli [67]. A mar locus (or a Mar-like
phenotype) is, in fact, widely distributed among
Gram-negative bacteria [13,68,69]. Increasingly,
resistance to fluoroquinolones in Gram-negative
bacteria results from a combination of enhanced
expression of multidrug efflux systems and target
site mutations [25,39,48,70–73]. It may be that
efflux was also a contributing (but overlooked)
factor in earlier reports of fluoroquinolone resist-
ance attributed to target site mutations. Signifi-
cantly, loss of multidrug efflux (AcrAB in E. coli
[74] or Salmonella typhimurium [39]; MexAB–
OprM in P. aeruginosa [75]; CmeABC in Camp.
jejuni) can undermine the resistance provided by
target site mutations, in some instances rendering
the mutants susceptible despite the presence of
these target site mutations [39,74,75]. These
results highlight both the significance of the
contribution of efflux mechanisms to fluoroqui-
nolone resistance in Gram-negative organisms,
and the probable utility of efflux inhibitors in
countering resistance attributable to efflux and
target site mutations.
O V E R C O M I N G E F F L U X - M E D I A T E D
M U L T I R E S I S T A N C E
An obvious approach to overcoming resistance
mediated by efflux mechanisms is to target them
directly (i.e., develop efflux inhibitors) or to
develop antimicrobials that are less impacted by
efflux (i.e., are poor substrates for these efflux
systems). To date, several inhibitors active against
the multidrug efflux systems of Gram-negative
bacteria have been described that are, for example,
effective at reversing efflux-mediated multiresis-
tance [4,76,77]. The glycylcycline tigecycline
(GAR-936), originally identified as being unaffec-
ted by (for example) the tetracycline-specific Tet
efflux determinants found in E. coli, also appears
to be an inferior substrate for the multidrug efflux
systems of P. aeruginosa [78] and is active against
multiresistant S. maltophilia and A. baumannii [79].
Nonetheless, P. aeruginosa is still generally resis-
tant to this agent, which is exported by the
MexAB–OprM, MexCD–OprJ and MexXY–OprM
multidrug efflux systems of this organism [78].
Moreover, the notably reduced susceptibility of
Proteus mirabilis to tigecycline was recently
explained by the activity of the AcrAB multidrug
efflux system of this organism, which readily
accommodates this agent [80]. The likelihood that
many novel agents may be substrates for these
highly accommodating efflux systems [81] needs
to inform current antimicrobial strategies that
focus on developing novel agents or novel drug tar-
gets [82]. Given the synergy that exists between
outer-membrane impermeability and active drug
efflux, targeting the outer-membrane barrier is also
proposed as an effective way of compromising
efflux-mediated multiresistance [13]. Finally,
therapeutic approaches based on vaccines, immu-
nomodulation, cationic antibacterial peptides and
phages, to name just a few, may become increas-
ingly important in treating multiresistant Gram-
negative infections, benefiting as they do from an
‘insensitivity’ to drug efflux mechanisms [4].
N A T U R A L F U N C T I O N O F
M U L T I D R U G E F F L U X S Y S T E M S
There is much discussion in the literature as to the
natural function of bacterial multidrug efflux
systems, with evidence for induction of the sys-
tems by agents known to be exported, providing
support for proposed roles in protection against
noxious exogenous substances. For example, the
MexXY–OprM system of P. aeruginosa is both
induced by and exports several antibiotics, inclu-
ding gentamicin, erythromycin and tetracycline
[83], and, as such, efflux of these agents may be its
intended function. However, it is also possible that
the action of these agents on their ribosome targets
stimulates the production of cellular product(s)
which are the intended MexXY–OprM substrates
and, thus, induce expression of this efflux. The
MexCD–OprJ efflux system of this same organism
is also inducible by a number of its non-antibiotic
substrates (e.g., the dyes rhodamine 6G, acrifla-
vine and ethidium bromide and the biocides
benzallcon chloride and chlorhexid), although
not by any clinically relevant antibiotics [84a].
The observed inducibility of the E. coli AcrAB
system by toxic fatty acids [85], and the demon-
strated role of AcrAB in the export of and
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resistance to bile salts [86], have been cited as
support for a role for AcrAB in protecting the cell
from the action of these agents in the gut [85],
although clearly there is no evidence for antibiotics
being the intended substrate. Similarly, a protect-
ive function has been attributed to the MtrCDE
system, which provides resistance to faecal lipids
in rectal isolates of N. gonorrhoeae [87] and, prob-
ably, bile salts known to bathe mucous membranes
[88]. Still, the ability to accommodate bile salts is
not, in itself, proof of a protective function for
either efflux system, inasmuch as many of the so-
called multidrug efflux systems of (for example) E.
coli accommodate and provide resistance to bile
salts [54]. It would appear unlikely that a given
organism would devote several systems to the
export of bile salts, and so these agents may be just
some of many, perhaps unintended, substrates for
these highly accommodating, broadly specific
efflux systems.
Export of bacterial products is also a proposed
function for these multidrug efflux systems, with
a previous review implicating byproducts of
metabolism as probable substrates for these efflux
systems [89]. The upregulation of the E. coli
AcrAB efflux system in strains with mutations
in central biosynthetic pathways, possibly as a
result of accumulation of pathway intermediates
[90], certainly support this idea. The fact that a
homologue, IefABC, of the AcrAB and MexAB
efflux systems exports isoflavanoids in the plant
pathogen Agrobacterium tumefaciens adds support
to suggestions that non-antimicrobials are the
intended substrates of many of these efflux
systems [91]. Finally, efflux homologues of the
RND–MFP–OMF type are broadly conserved
among Gram-negative organisms, with multiple
examples present in many species (Table 1) that
are invariably linked to regulatory genes, imply-
ing individual control of these systems and, thus,
distinct functions in the cell. So, while these
systems, even in a single organism, accommodate
many of the same antimicrobials, it is unlikely
that their export is the primary function of these
systems. Still, given their contribution to resist-
ance against many clinically relevant agents, and
their broad distribution, it is clear that these efflux
systems are important determinants of antimicro-
bial resistance in many Gram-negative pathogens,
and that their operation in these organisms is
likely to compromise the use of current and yet to
be developed agents.
C O N C L U S I O N S
Multiresistance is a significant problem in medi-
cine because it limits chemotherapeutic options.
The recognition that many instances of intrinsic
and acquired antimicrobial (including biocide)
resistance are attributable, at least in part, to the
activity of broadly specific multidrug efflux sys-
tems, and that these are broadly conserved in
Gram-negative pathogens, means that antimicro-
bial (including biocide) use and development
must be informed by the possible impact of efflux.
While multidrug efflux might compromise the
activity of novel agents that could be efflux
substrates, a possible bigger concern is that potent
new agents might be missed in, for example,
whole cell screens precisely because they are
excluded from the cell by these efflux mecha-
nisms [81]. Current efforts aimed at developing
multidrug efflux inhibitors [77,92] that can be
used in combination with existing and, possibly,
novel agents (a strategy that has proven effective
in the case of b-lactam–b-lactamase inhibitors
[93]) may ultimately prove important in preser-
ving a strategy for treating infectious disease
based on chemotherapeutic agents. Such efforts
will be aided by recent reports of the three-
dimensional structures of components of the
RND–MFP–OMF pump family [94–96], and by
the identification of the drug recognition regions
of the RND component [97–101], both of which
can assist in rational inhibitor design.
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